Surrozen is a biotechnology company that engineers multifunctional antibodies to selectively activate Wnt signaling pathways for tissue repair and regeneration. Its development program centers on ophthalmic conditions such as diabetic macular edema and wet age-related macular degeneration, using bispecific constructs that combine pathway activation with anti-VEGF or other mechanisms.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 1 | — | 21.8 | — |
| Q3 2025 | 1 | — | -71.6 | — |
| Q4 2025 | 0.5 | — | -183.2 | — |
| Q1 2026 | 5 | — | -127.5 | — |
| Q2 2026 | 5 | 408.6% | 32 | 46.9% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Alico, Inc. (ALCO), Archimedes Tech SPAC Partners II Co. (ATII), Cantor Equity Partners I, Inc. (CEPO), First Northern Community Bancorp (FNRN), Premium Catering (Holdings) Limited (PC), EHang Holdings Limited (EH)